尼洛替尼对比达沙替尼在新诊断慢性髓性白血病中达到MR4.5的随机JALSG CML212研究
日本成人白血病研究组(JALSG)开展前瞻性随机3期CML212研究,将454例新诊断慢性期慢性髓性白血病(CML-CP)患者随机分配至尼洛替尼300mg每日两次组或达沙替尼100mg每日一次组(各227例),比较18个月时MR4.5累积达标率。结果显示尼洛替尼组32.6%(95%CI 26.5-39.1)与达沙替尼组30.8%(95%CI 24.9-37.3)无显著差异(P=.66)。
要点
- 18个月MR4.5累积达标率尼洛替尼组32.6% vs 达沙替尼组30.8%(P=.66),无显著差异。
- 12、18、24、36个月早期分子反应、完全细胞遗传学反应及主要分子反应累积达标率两组几乎相同。
- 无进展生存(PFS)与总生存(OS)两组无显著差异(PFS P=.58;OS P=.64)。
核心结论
- 尼洛替尼与达沙替尼对新诊断CML-CP患者可能同等有效。
研究设计与样本
- JALSG开展的前瞻性随机3期CML212研究,纳入454例新诊断CML-CP患者,随机分配至尼洛替尼300mg每日两次组(n=227)或达沙替尼100mg每日一次组(n=227)。
- 每3个月监测BCR::ABL1信使RNA水平,按欧洲白血病网2009标准判定失败或不耐受时停止研究治疗。
主要发现
- 18个月MR4.5累积达标率尼洛替尼组32.6%(95%CI 26.5-39.1) vs 达沙替尼组30.8%(95%CI 24.9-37.3),无显著差异(P=.66)。
- 12、18、24、36个月早期分子反应、完全细胞遗传学反应及主要分子反应累积达标率两组几乎相同。
- 无进展生存(PFS)与总生存(OS)两组经log-rank检验无显著差异(PFS P=.58;OS P=.64)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Deep molecular response (DMR) is a prerequite for treatment-free remission (TFR) in chronic myeloid leukemia in chronic phase (CML-CP). The JALSG (Japan Adult Leukemia Study Group) conducted a prospective randomized phase 3 CML212 study for de novo CML-CP to compare the cumulative achievement of molecular response 4.5 (MR4.5; international scale BCR::ABL1 ≤0.0032%) by 18 months between nilotinib and dasatinib treatment as a primary end point. A total of 454 patients were randomly assigned to the 300 mg nilotinib twice daily arm or to the 100 mg dasatinib daily arm (both n = 227). BCR::ABL1 messenger RNA levels were monitored every 3 months. Study treatment was stopped if the patients were judged as failure according to the European LekemiaNet 2009 criteria or showed intolerance. The cumulative achievement rates of MR4.5 by 18 months were 32.6% (95% confidence interval [CI], 26.5-39.1) in the nilotinib arm and 30.8% (95% CI, 24.9-37.3) in the dasatinib arm with no significant difference (P = .66). The cumulative achievement rates of early molecular response, complete cytogenetic response, and major molecular response by 12, 18, 24, and 36 months were almost the same between the 2 arms. There was no significant difference in progression-free survival (PFS) or overall survival (OS) between the 2 arms by log-rank tests (PFS, P = .58; OS, P = .64). These results suggest that nilotinib and dasatinib would be equally effective for patients with de novo CML-CP. This trial was registered in the University Hospital Medical Information Network Clinical Trials Registry as #UMIN000007909.
引用
- Matsumura I, Ohtake S, Atsuta Y, et al. Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study. Blood Adv. 2024. PMID: 38968156. doi:10.1182/bloodadvances.2024012655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。